ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Zealand Pharma (ZEAL.CO)
Zealand Pharma stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Nasdaq Copenhagen · Denmark
DKK 226.00▲ +1.21%
Prices as of Oct 27, 2026 · DKK
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Zealand Pharma in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Zealand Pharma
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Zealand Pharma a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between DKK 207.44 and DKK 244.44; in 9 out of 10, between DKK 179.35 and DKK 282.73. Estimated annual volatility is 40%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- DKK 15.2B
- Market cap (USD)
- $2.3B
- P/E ratio
- 6.2
- 52-week high
- DKK 556.00
- 52-week low
- DKK 220.60
- Revenue (12 months)
- DKK 4.6B
- Operating margin
- 85.9%
- Net margin
- 59.0%
- Beta
- 0.61
What this means
ATLAS does not publish a fair value for ZEAL.CO right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks ZEAL.CO has traded between DKK 220.60 and DKK 556.00. Today it is 59.4% below that high and 2% above its low.
On the business: net margin is 59.0%; it trades at 6.2 times earnings.
Its beta is 0.61: it tends to move less than the market.
About the company
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.
Want to see everything about Zealand Pharma?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Zealand Pharma do?
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.
What is the chance ZEAL.CO goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, ZEAL.CO ends the month between DKK 207.44 and DKK 244.44.
How big is Zealand Pharma and what is its P/E ratio?
Zealand Pharma's market capitalization is DKK 15.2B. Its price-to-earnings (P/E) ratio is 6.2: you pay DKK 6.16 for each DKK 1.00 of yearly earnings.
How volatile is ZEAL.CO?
ATLAS estimates annual volatility at 40%. In a typical month, half of the outcomes end between DKK 207.44 and DKK 244.44.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer